Ionis Pharmaceuticals, Inc. Increase (Decrease) in Contract with Customer, Asset
Ionis Pharmaceuticals, Inc. (IONS) reported Increase (Decrease) in Contract with Customer, Asset of -$7.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2026-06-30 was -$14.84M, a 215.27% decline year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2026-03-31 was $7.63M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2025-12-31 was $41.45M, a 44.18% decline year-over-year.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2025-09-30 was -$27.97M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for fiscal 2025 was -$26.13M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for fiscal 2024 was -$5.59M, a 107.76% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for fiscal 2023 was $72.06M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, asset for fiscal 2022 was -$36.36M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$7.21M 10-Q · filed 2026-07-29 | $34.24M derived: sum of 3 quarters · filed 2026-07-29 | $6.26M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $7.63M 10-Q · filed 2026-04-29 | $49.08M derived: sum of 2 quarters · filed 2026-04-29 | $21.10M derived: sum of 3 quarters · filed 2026-04-29 | $33.98M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $41.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.48M derived: sum of 2 quarters · filed 2026-02-26 | $26.35M derived: sum of 3 quarters · filed 2026-07-29 | -$26.13M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$27.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$15.10M derived: sum of 2 quarters · filed 2026-07-29 | -$67.58M 10-Q · filed 2025-10-29 | $6.68M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $12.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$39.61M 10-Q · filed 2026-07-29 | $34.65M derived: sum of 3 quarters · filed 2026-07-29 | $25.32M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$52.48M 10-Q · filed 2026-04-29 | $21.78M derived: sum of 2 quarters · filed 2026-04-29 | $12.45M derived: sum of 3 quarters · filed 2026-04-29 | $34.57M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $74.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $64.93M derived: sum of 2 quarters · filed 2026-02-26 | $87.05M derived: sum of 3 quarters · filed 2026-02-26 | -$5.59M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$9.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $12.79M derived: sum of 2 quarters · filed 2025-10-29 | -$79.85M 10-Q · filed 2025-10-29 | -$124.61M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $22.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$70.52M 10-Q · filed 2025-07-30 | -$115.27M derived: sum of 3 quarters · filed 2026-02-26 | -$714.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$92.64M 10-Q · filed 2025-04-30 | -$137.39M derived: sum of 2 quarters · filed 2026-02-26 | -$22.83M derived: sum of 3 quarters · filed 2026-02-26 | -$8.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$44.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $69.81M derived: sum of 2 quarters · filed 2026-02-26 | $83.68M derived: sum of 3 quarters · filed 2026-02-26 | $72.06M 10-K · filed 2026-02-26 |
| 2023-09-30 | $114.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $128.44M derived: sum of 2 quarters · filed 2024-11-06 | $116.81M 10-Q · filed 2024-11-06 | $135.71M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $13.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.25M 10-Q · filed 2024-08-01 | $21.15M derived: sum of 3 quarters · filed 2025-02-19 | $21.04M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$11.62M 10-Q · filed 2024-05-07 | $7.27M derived: sum of 2 quarters · filed 2025-02-19 | $7.16M derived: sum of 3 quarters · filed 2025-02-19 | -$12.21M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $18.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $18.79M derived: sum of 2 quarters · filed 2025-02-19 | -$584.00K derived: sum of 3 quarters · filed 2025-02-19 | -$36.36M 10-K · filed 2025-02-19 |
| 2022-09-30 | -$106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$19.48M derived: sum of 2 quarters · filed 2023-11-02 | -$55.25M 10-Q · filed 2023-11-02 | -$2.42M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$19.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$55.15M 10-Q · filed 2023-08-09 | -$2.32M derived: sum of 3 quarters · filed 2024-02-21 | -$17.25M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$35.77M 10-Q · filed 2023-05-03 | $17.05M derived: sum of 2 quarters · filed 2024-02-21 | $2.12M derived: sum of 3 quarters · filed 2024-02-21 | $2.73M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $52.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $37.89M derived: sum of 2 quarters · filed 2024-02-21 | $38.50M derived: sum of 3 quarters · filed 2024-02-21 | -$14.31M 10-K · filed 2024-02-21 |
| 2021-09-30 | -$14.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$14.33M derived: sum of 2 quarters · filed 2022-11-09 | -$67.14M 10-Q · filed 2022-11-09 | -$29.91M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $607.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$52.20M 10-Q · filed 2022-08-09 | -$14.97M derived: sum of 3 quarters · filed 2023-02-22 | -$3.83M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | -$52.81M 10-Q · filed 2022-05-04 | -$15.58M derived: sum of 2 quarters · filed 2023-02-22 | -$4.44M derived: sum of 3 quarters · filed 2023-02-22 | -$5.21M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $37.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $48.37M derived: sum of 2 quarters · filed 2023-02-22 | $47.60M derived: sum of 3 quarters · filed 2023-02-22 | $13.17M 10-K · filed 2023-02-22 |
| 2020-09-30 | $11.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $10.37M derived: sum of 2 quarters · filed 2021-11-03 | -$24.06M 10-Q · filed 2021-11-03 | -$10.10M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$771.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$35.20M 10-Q · filed 2021-08-04 | -$21.24M derived: sum of 3 quarters · filed 2022-02-25 | -$3.78M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$34.43M 10-Q · filed 2021-05-05 | -$20.47M derived: sum of 2 quarters · filed 2022-02-25 | -$3.01M derived: sum of 3 quarters · filed 2022-02-25 | $18.15M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $13.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $31.42M derived: sum of 2 quarters · filed 2022-02-25 | $52.58M derived: sum of 3 quarters · filed 2022-02-25 | $47.67M 10-K · filed 2022-02-25 |
| 2019-09-30 | $17.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $38.62M derived: sum of 2 quarters · filed 2020-11-04 | $33.72M 10-Q · filed 2020-11-04 | $34.34M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $21.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $16.25M 10-Q · filed 2020-08-05 | $16.88M derived: sum of 3 quarters · filed 2021-02-24 | $14.85M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$4.91M 10-Q · filed 2020-05-06 | -$4.28M derived: sum of 2 quarters · filed 2021-02-24 | -$6.31M derived: sum of 3 quarters · filed 2021-02-24 | -$26.41M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $628.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$1.40M derived: sum of 2 quarters · filed 2021-02-24 | -$21.50M derived: sum of 3 quarters · filed 2021-02-24 | -$47.59M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$2.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$22.13M derived: sum of 2 quarters · filed 2019-11-06 | -$48.22M 10-Q · filed 2019-11-06 | -$28.19M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$20.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$46.19M 10-Q · filed 2019-08-08 | -$26.16M derived: sum of 3 quarters · filed 2020-03-02 | -$33.85M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$26.10M 10-Q · filed 2019-05-09 | -$6.07M derived: sum of 2 quarters · filed 2020-03-02 | -$13.76M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $20.03M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $12.34M derived: sum of 2 quarters · filed 2020-03-02 | -$45.09M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$7.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$65.12M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | -$57.43M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $96.69M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |